Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.
Also called NCT02749890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 321 participants
- Sponsor
- Registry
-
NCT02749890
-
- Other papers using this trial's data
- Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02749890. Randomized; no masking; primary purpose treatment. Start 2016-05-09 (actual); primary completion 2018-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
- Acronym
- LIXILAN JP-O1
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Oral anti-diabetic drugs
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02749890- Content hash
fb9ecb18f268a32d1bfddeaf102174de224db915335cfb9b300309f1293dff5b